Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis

BACKGROUND: After the approval of pazopanib for the treatment of soft tissue sarcoma (STS), pneumothorax was reported as an unexpected adverse event during pazopanib treatment. The incidence and risk factors of pneumothorax during pazopanib treatment for STSs have not been established yet. METHODS:...

詳細記述

保存先:
書誌詳細
出版年:BMC Cancer
主要な著者: Nakano, Kenji, Motoi, Noriko, Tomomatsu, Junichi, Gokita, Tabu, Ae, Keisuke, Tanizawa, Taisuke, Matsumoto, Seiichi, Takahashi, Shunji
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2016
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5035441/
https://ncbi.nlm.nih.gov/pubmed/27663525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2786-z
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料